Inici › Limfoma difús de cèl·lules B grans › Massachusetts › Boston
Assaigs clínics de Limfoma difús de cèl·lules B grans a Boston, MA
16 estudis de Limfoma difús de cèl·lules B grans busquen participants en centres de Boston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
ReclutantFase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ReclutantFase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
ReclutantFase 3
- Beth Israel Deaconess Medical Center, Boston
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
ReclutantFase 2
- Beth Israel Deaconess Medical Center ( Site 0161), Boston
- Dana Farber Cancer Institute ( Site 0111), Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
ReclutantFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ReclutantFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
ReclutantFase 1/2
- Dana-Farber Cancer Institute ( Site 1013), Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
ReclutantFase 2
- Boston Medical Center, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
ReclutantFase 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
ReclutantEstudi observacional
- Dana Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
ReclutantFase 2
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
ReclutantFase 2
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
ReclutantFase 1
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
ReclutantFase 1
- Massachusetts General Hospital, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
ReclutantFase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
ReclutantFase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assaigs de Limfoma difús de cèl·lules B grans en altres ciutats
- New York City, NY21 estudis
- Baldwin Park, CA19 estudis
- Chicago, IL18 estudis
- Houston, TX17 estudis
- Los Angeles, CA17 estudis
- Milwaukee, WI16 estudis
- Nashville, TN15 estudis
- Portland, OR15 estudis
- Philadelphia, PA15 estudis
- Durham, NC14 estudis
- Dallas, TX13 estudis
- Seattle, WA12 estudis
Altres estudis a Boston
- Càncer de mama111 estudis
- Càncer de pulmó de cèl·lules no petites90 estudis
- Càncer (tots els tipus)86 estudis
- Càncer colorrectal63 estudis
- Càncer metastàtic63 estudis
- Càncer de pulmó62 estudis
- Càncer d'ovari61 estudis
- Càncer de pròstata59 estudis
- Depressió52 estudis
- Càncer d'endometri50 estudis
- Insuficiència cardíaca44 estudis
- Leucèmia mieloide aguda44 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.